Covered recipient · General Payments record
MARK JAFFE
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,859.38
126 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,849.78 | 123 |
| Consulting Fee | $750.00 | 1 |
| Grant | $239.52 | 1 |
| Education | $20.08 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $1,362.01 | 35 |
| Amgen Inc. | $401.58 | 44 |
| ABBVIE INC. | $361.90 | 7 |
| AstraZeneca Pharmaceuticals LP | $147.00 | 7 |
| Horizon Therapeutics plc | $134.66 | 17 |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $134.14 | 3 |
| PFIZER INC. | $65.64 | 2 |
| Aurinia Pharma U.S., Inc. | $53.37 | 2 |
| Genentech, Inc. | $50.21 | 2 |
| Lilly USA, LLC | $47.30 | 2 |
| UCB, Inc. | $34.07 | 2 |
| Octapharma USA, Inc. | $30.38 | 1 |
| Novartis Pharmaceuticals Corporation | $21.49 | 1 |
| Sobi, Inc | $15.63 | 1 |
Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARK JAFFE
NPI 1730160615 · CMS profile ID 78924
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
HOLLYWOOD, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1730160615?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARK JAFFE, NPI 1730160615, CMS profile ID 78924. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730160615?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). MARK JAFFE, NPI 1730160615, CMS profile ID 78924. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730160615?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- MARK JAFFE, NPI 1730160615, CMS profile ID 78924, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1730160615?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
126 matching records · $2,859.38 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 126.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $19.74 | 07/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401545 | CMS |
| Amgen Inc. | $5.82 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401503 | CMS |
| Janssen Biotech, Inc. | $6.96 | 07/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673067 | CMS |
| Lilly USA, LLC | $23.51 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918222701 | CMS |
| Amgen Inc. | $4.24 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401501 | CMS |
| Horizon Therapeutics plc | $6.85 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637643 | CMS |
| Amgen Inc. | $5.61 | 07/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401499 | CMS |
| ABBVIE INC. | $18.88 | 07/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892908763 | CMS |
| Janssen Biotech, Inc. | $18.18 | 07/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673061 | CMS |
| Amgen Inc. | $14.86 | 06/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933769125 | CMS |
| Amgen Inc. | $20.08 | 06/29/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933769127 | CMS |
| Amgen Inc. | $6.17 | 06/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401497 | CMS |
| Amgen Inc. | $6.28 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401495 | CMS |
| Horizon Therapeutics plc | $7.26 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637641 | CMS |
| Horizon Therapeutics plc | $4.84 | 06/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637639 | CMS |
| Amgen Inc. | $6.14 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401481 | CMS |
| Amgen Inc. | $6.57 | 06/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401479 | CMS |
| Janssen Biotech, Inc. | $12.63 | 06/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673053 | CMS |
| Lilly USA, LLC | $23.79 | 06/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918181341 | CMS |
| Amgen Inc. | $6.43 | 05/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401477 | CMS |
| ABBVIE INC. | $20.87 | 05/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892908759 | CMS |
| Genentech, Inc. | $20.25 | 05/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950777231 | CMS |
| Amgen Inc. | $5.04 | 05/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401475 | CMS |
| Horizon Therapeutics plc | $8.36 | 05/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637637 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.44 | 05/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914966697 | CMS |
| Amgen Inc. | $5.83 | 05/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401473 | CMS |
| Janssen Biotech, Inc. | $13.54 | 05/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673047 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.32 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915252243 | CMS |
| Horizon Therapeutics plc | $12.53 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637635 | CMS |
| Amgen Inc. | $6.06 | 05/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401471 | CMS |
| PFIZER INC. | $34.31 | 05/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949124659 | CMS |
| Amgen Inc. | $5.27 | 05/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401469 | CMS |
| Horizon Therapeutics plc | $5.90 | 04/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637633 | CMS |
| Janssen Biotech, Inc. | $36.18 | 04/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673041 | CMS |
| Amgen Inc. | $5.17 | 04/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401467 | CMS |
| Amgen Inc. | $3.00 | 04/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401493 | CMS |
| Amgen Inc. | $28.08 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401491 | CMS |
| Amgen Inc. | $6.19 | 04/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401489 | CMS |
| Amgen Inc. | $26.73 | 04/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401543 | CMS |
| Horizon Therapeutics plc | $5.38 | 04/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637631 | CMS |
| Janssen Biotech, Inc. | $14.12 | 04/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673029 | CMS |
| Amgen Inc. | $7.64 | 04/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401487 | CMS |
| Aurinia Pharma U.S., Inc. | $26.11 | 03/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954082913 | CMS |
| Amgen Inc. | $4.90 | 03/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401485 | CMS |
| Janssen Biotech, Inc. | $13.47 | 03/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673207 | CMS |
| Janssen Biotech, Inc. | $27.94 | 03/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673201 | CMS |
| Amgen Inc. | $5.92 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939401483 | CMS |
| Janssen Biotech, Inc. | $15.65 | 03/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673195 | CMS |
| Janssen Biotech, Inc. | $12.80 | 03/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885673023 | CMS |
| Horizon Therapeutics plc | $10.01 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937637629 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $382,214.48 | 44 |
| PY2024 | Principal investigator | $168,150.39 | 31 |
| PY2023 | Principal investigator | $82,355.96 | 24 |
| PY2022 | Principal investigator | $97,710.81 | 48 |
| PY2021 | Principal investigator | $70,502.35 | 28 |
| PY2020 | Principal investigator | $7,500.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
44 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $307.08 | 12/31/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202535087 |
| Principal investigator 1 | Eli Lilly and Company | $4,443.95 | 12/23/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187880033 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,530.94 | 12/17/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289772 |
| Principal investigator 1 | ABBVIE INC. | $8,719.31 | 12/04/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202526712 |
| Principal investigator 1 | ABBVIE INC. | $18,300.92 | 11/05/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202521553 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,866.57 | 10/23/2025 | Non-covered Recipient Entity GNP RESEARCH | A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) | No dispute reported | 06/30/2026 | 1190311919 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,000.00 | 10/08/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286551 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 10/08/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286553 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,200.00 | 10/08/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286557 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,291.25 | 09/16/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122574 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $82,630.95 | 09/12/2025 | Non-covered Recipient Entity Gnp Research | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235997077 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $25,588.00 | 09/05/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225336111 |
| Principal investigator 1 | ABBVIE INC. | $3,963.92 | 09/04/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202508584 |
| Principal investigator 1 | ABBVIE INC. | $5,300.00 | 08/06/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202503577 |
| Principal investigator 1 | ABBVIE INC. | $19,775.00 | 07/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202494531 |
| Principal investigator 1 | ABBVIE INC. | $2,200.00 | 07/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202494533 |
| Principal investigator 1 | ABBVIE INC. | $2,200.00 | 07/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202494535 |
| Principal investigator 1 | ABBVIE INC. | $19,900.00 | 07/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202494537 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118405 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $70.20 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118418 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $290.25 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118429 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $240.00 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118435 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $80.00 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118441 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $114.75 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122589 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $290.25 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122594 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,039.50 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122601 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $101.25 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122607 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $317.25 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122613 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $110.00 | 06/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122621 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $440.00 | 06/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118399 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $290.25 | 06/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118412 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $864.00 | 06/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192118425 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,498.50 | 06/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122568 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $118.80 | 06/02/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192172575 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,250.00 | 05/12/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1175418656 |
| Principal investigator 2 | E.R. Squibb & Sons, L.L.C. | $23,417.55 | 05/09/2025 | Non-covered Recipient Entity Denver Arthritis Clinic | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235997730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 04/07/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1175418642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,250.00 | 03/31/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1175418636 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,290.00 | 03/27/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1175418649 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,809.30 | 03/10/2025 | Non-covered Recipient Entity GNP RESEARCH | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190310516 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $32,497.48 | 02/10/2025 | Non-covered Recipient Entity GNP RESEARCH | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL | No dispute reported | 06/30/2026 | 1190310520 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,599.50 | 01/28/2025 | Non-covered Recipient Entity GNP CONSULTANTS LLC | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | No dispute reported | 06/30/2026 | 1192122582 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $897.96 | 01/09/2025 | Non-covered Recipient Entity GNP RESEARCH | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190310518 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $29,802.30 | 01/01/2025 | Non-covered Recipient Entity GNP RESEARCH | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | No dispute reported | 06/30/2026 | 1190310522 |